NasdaqGM:AXSMPharmaceuticals
The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Balipodect Licensing Deal From Takeda
Axsome Therapeutics recently obtained exclusive global rights from Takeda Pharmaceutical to balipodect (TAK-063), a selective PDE10A inhibitor for central nervous system disorders including schizophrenia and Tourette syndrome, and plans Phase 3 trial-enabling work during 2026.
This deal broadens Axsome’s late-stage neuropsychiatry pipeline with a clinically tested asset that has shown a favorable safety and tolerability profile, potentially reshaping its long-term portfolio mix.
We’ll now...